Vecta Pharmaceuticals

Company Overview

Snapshot

Founded in May 2001, Vecta Pharmaceuticals operates with 1–10 employees. The company is currently in a Pre-Funding stage, with its status updated to Non Active in January 2018.

Business overview

Vecta Pharmaceuticals is a Health Tech & Life Sciences company focused on developing pharmaceutical treatments for upper gastrointestinal tract diseases. Its core product, VECAM-111, is an improved proton pump inhibitor (PPI) designed to address symptoms of gastroesophageal reflux disease (GERD) not adequately managed by existing therapies. VECAM-111 offers flexible dosing and nocturnal efficacy, eliminating the need for food to activate the PPI. The drug utilizes a unique formulation with an inner succinic acid capsule and an outer enteric-coated PPI, esomeprazole, to stimulate proton pumps and treat GERD. The company operates within the Pharmaceuticals sector, targeting patients in the Healthcare and Life Sciences markets.

Company Intelligence Q&A

What is Vecta Pharmaceuticals' primary focus?

Vecta Pharmaceuticals specializes in developing pharmaceutical treatments for diseases affecting the upper gastrointestinal tract, primarily focusing on gastroesophageal reflux disease (GERD).

What is VECAM-111?

VECAM-111 is Vecta Pharmaceuticals' flagship product, an improved proton pump inhibitor (PPI) designed to treat GERD symptoms by offering flexible dosing, nocturnal efficacy, and eliminating the need for food to activate the PPI.

What is the unique mechanism of action for VECAM-111?

VECAM-111 capsules contain an inner succinic acid (SA) capsule and an outer enteric-coated PPI (esomeprazole). This formulation ensures the PPI is present when the SA capsule dissolves, stimulating proton pump activity for effective GERD treatment.

When was Vecta Pharmaceuticals founded?

Vecta Pharmaceuticals was founded in May 2001.

What is the current status of Vecta Pharmaceuticals?

Vecta Pharmaceuticals was updated to Non Active in January 2018.